SLC5A8 is a conditional tumor suppressor in colon linked to dietary fiber content
SLC5A8 is a conditional tumor suppressor in colon linked to dietary fiber content
批准号:
9751215
负责人:
VADIVEL GANAPATHY
金额:
$33.93万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-08-01 至 2020-07-31
关键词:
Adrenergic alpha-AntagonistsAffinityAnti-inflammatoryAutomobile DrivingAzoxymethaneBiologicalBiological ModelsBloodButyratesCD4 Positive T LymphocytesCellsColitisColonColon CarcinomaCoupledDataDendritic CellsDietDietary FiberDiffuseEcologyEpigenetic ProcessEpithelial CellsExposure toFaceFermentationFiberGenerationsGenesGenotypeGoalsHistone AcetylationHistone DeacetylaseHistone Deacetylase InhibitorImmuneImmunosuppressive AgentsIn VitroInflammationInflammatoryIntakeInterferon Type IIKnockout MiceLamina PropriaLinkLogicMaintenanceMammary glandMediatingModelingMolecularMucosal Immune SystemMucous MembraneMusMyeloid CellsPathway interactionsPhenotypePhylogenetic AnalysisProcessRegulatory T-LymphocyteRoleSeveritiesSignal TransductionSodium Dextran SulfateT-LymphocyteTestingTretinoinTumor Suppressor ProteinsVolatile Fatty AcidsWild Type Mousebasecolon carcinogenesiscolon microbiotadifferential expressiondysbiosisfunctional statusgene interactiongut microbiotain vivomalignant breast neoplasmmicrobialpublic health relevancetranscriptometumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): LC5A8 was first identified as a candidate tumor suppressor in colon. We showed that it is a Na+-coupled transporter for short-chain fatty acids (SCFAs) and that its ability to energize the cellular entry of the SCFA butyrate, a bacterial fermentation product of dietary fiber and an inhibitor of histone deacetylases, underlies its tumor-suppressive function in colon. However, in vivo studies with Slc5a8-/- mice failed to support such a function. Now we found that the ability of Slc5a8 to protect against colitis and colon cancer is dictated by dietary fiber content. The transporter is obligatory for the beneficial
effects of SCFAs in colonic epithelial cells only when the luminal concentrations of SCFAs are low (low fiber intake). In contrast, the obligatory role of the transporter in mucosal immune cells
is not dependent on dietary fiber content. We hypothesize that SLC5A8 is a conditional tumor suppressor in colon and is essential for the maintenance of the tolerogenic phenotype of the mucosal immune system, but the obligation of its role in colonic epithelial cells and LP immune cells is differentially influenced by the dietary fiber content. In addition, we hypothesize that SLC5A8 and optimal dietary fiber protect against bacterial dysbiosis in the gut, which is known to drive inflammation and cancer in colon. We will test these hypotheses by completing the following specific aims: (1A) Show that Slc5a8 is essential for the immunotolerant phenotype of the mucosal immune system by qualitatively and quantitatively increasing the number of anti- inflammatory dendritic cells and immunosuppressive Tregs in colon, and determine the relevance of dietary fiber content to this process; (1B) Delineate the phylogenetic profile of gut microbiota in wild type and Slc5a8-/- mice under low-fiber & high-fiber conditions to determine if bacterial dysbiosis occurs in the gut as a consequence of Slc5a8 deletion and/or low dietary fiber, thus driving the increased severity of colitis and enhanced colon cancer observed in Slc5a8-/- mice under low-fiber dietary conditions; (2A) Interrogate the contribution of Slc5a8 in colonic epithelial cells versus Slc5a8 in myeloid cells to the protection against experimental colitis under low-fiber & high-fiber dietary conditions using conditional knockout mice with selective deletion of Slc5a8 either in epithelial cells or in myeloid cells; (2B) Interrogate the contribution of Slc5a8 in colonic epithelial cells versus Slc5a8 in myeloid cells to the protection
against experimental colon cancer under low-fiber & high-fiber dietary conditions using conditional knockout mice with selective deletion of Slc5a8 either in epithelial cells or in myeloi cells; (3) Dissect the changes in histone acetylation and consequent transcriptome landscape in colonic epithelial cells and LP dendritic cells that are responsible for the ability of Slc5a8 to protect against colitis and colon cancer under low-fiber & high-fiber dietary conditions.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1016/j.bbcan.2017.05.003
发表时间:
2017-08
期刊:
Biochimica et biophysica acta. Reviews on cancer
影响因子:
--
作者:
[Ristic B, Bhutia YD, Ganapathy V]
通讯作者:
Ganapathy V
DOI:
10.1002/cphy.c170014
发表时间:
2017-12-12
期刊:
Comprehensive Physiology
影响因子:
5.8
作者:
[Sivaprakasam S, Bhutia YD, Yang S, Ganapathy V]
通讯作者:
Ganapathy V
DOI:
10.1007/s11888-017-0362-9
发表时间:
2017-04
期刊:
Current colorectal cancer reports
影响因子:
--
作者:
[Bhutia YD, Ogura J, Sivaprakasam S, Ganapathy V]
通讯作者:
Ganapathy V
DOI:
10.1002/cncr.33261
发表时间:
2021
期刊:
Cancer
影响因子:
6.2
作者:
[Wachtel,MitchellS]
通讯作者:
Wachtel,MitchellS
DOI:
10.1042/bj20150751
发表时间:
2016-05-01
期刊:
The Biochemical journal
影响因子:
--
作者:
[Bhutia YD, Babu E, Ramachandran S, Yang S, Thangaraju M, Ganapathy V]
通讯作者:
Ganapathy V
共 9 条
Amino acid transporter SLC38A5 as a drug target for TNBC: Evaluation with genetic and pharmacologic approaches
-
批准号:10576760
-
项目类别:
-
资助金额:$21.46万
-
财政年份:2022
-
负责人:VADIVEL GANAPATHY
-
依托单位:
Retinal Iron Homeostasis in Health and Disease
-
批准号:7889446
-
项目类别:
-
资助金额:$38.2万
-
财政年份:2010
-
负责人:VADIVEL GANAPATHY
-
依托单位:
"Starve the Tumor Cells to Death": SLC6A14 as a Drug Target for Colon Cancer
-
批准号:8077946
-
项目类别:
-
资助金额:$15.51万
-
财政年份:2010
-
负责人:VADIVEL GANAPATHY
-
依托单位:
Retinal Iron Homeostasis in Health and Disease
-
批准号:8035342
-
项目类别:
-
资助金额:$35.55万
-
财政年份:2010
-
负责人:VADIVEL GANAPATHY
-
依托单位:
Retinal Iron Homeostasis in Health and Disease
-
批准号:8231427
-
项目类别:
-
资助金额:$35.56万
-
财政年份:2010
-
负责人:VADIVEL GANAPATHY
-
依托单位:
"Starve the Tumor Cells to Death": SLC6A14 as a Drug Target for Colon Cancer
-
批准号:7963106
-
项目类别:
-
资助金额:$19.18万
-
财政年份:2010
-
负责人:VADIVEL GANAPATHY
-
依托单位:
Retinal Iron Homeostasis in Health and Disease
-
批准号:8423033
-
项目类别:
-
资助金额:$33.52万
-
财政年份:2010
-
负责人:VADIVEL GANAPATHY
-
依托单位:
Molecular Analysis of a Novel Opioid Peptide Transporter
-
批准号:7230316
-
项目类别:
-
资助金额:$14.27万
-
财政年份:2006
-
负责人:VADIVEL GANAPATHY
-
依托单位:
Molecular Analysis of a Novel Opioid Peptide Transporter
-
批准号:7127794
-
项目类别:
-
资助金额:$14.65万
-
财政年份:2006
-
负责人:VADIVEL GANAPATHY
-
依托单位:
Immune Tolerance; Sigma Receptor as a Therapeutic Target
-
批准号:6352379
-
项目类别:
-
资助金额:$21.53万
-
财政年份:2001
-
负责人:VADIVEL GANAPATHY
-
依托单位:
Immune Tolerance; Sigma Receptor as a Therapeutic Target
-
批准号:6534340
-
项目类别:
-
资助金额:$21.53万
-
财政年份:2001
-
负责人:VADIVEL GANAPATHY
-
依托单位:
Immune Tolerance; Sigma Receptor as a Therapeutic Target
-
批准号:6647090
-
项目类别:
-
资助金额:$21.53万
-
财政年份:2001
-
负责人:VADIVEL GANAPATHY
-
依托单位:
CARNITINE TRANSPORTERS: STRUCTURE, FUNCTION & REGULATION
-
批准号:6402792
-
项目类别:
-
资助金额:$25.55万
-
财政年份:2000
-
负责人:VADIVEL GANAPATHY
-
依托单位:
CARNITINE TRANSPORTERS: STRUCTURE, FUNCTION & REGULATION
-
批准号:6527302
-
项目类别:
-
资助金额:$25.55万
-
财政年份:2000
-
负责人:VADIVEL GANAPATHY
-
依托单位:
CARNITINE TRANSPORTERS: STRUCTURE, FUNCTION & REGULATION
-
批准号:6637291
-
项目类别:
-
资助金额:$25.55万
-
财政年份:2000
-
负责人:VADIVEL GANAPATHY
-
依托单位:
CARNITINE TRANSPORTERS: STRUCTURE, FUNCTION & REGULATION
-
批准号:6192658
-
项目类别:
-
资助金额:$25.55万
-
财政年份:2000
-
负责人:VADIVEL GANAPATHY
-
依托单位:
CELLULAR TARGETS FOR ABUSABLE DRUGS IN HUMAN PLACENTA
-
批准号:2749122
-
项目类别:
-
资助金额:$25.31万
-
财政年份:1996
-
负责人:VADIVEL GANAPATHY
-
依托单位:
POTOCYTOSIS AND PLACENTAL TRANSPORT FUNCTION
-
批准号:2673892
-
项目类别:
-
资助金额:$16.61万
-
财政年份:1996
-
负责人:VADIVEL GANAPATHY
-
依托单位:
POTOCYTOSIS AND PLACENTAL TRANSPORT FUNCTION
-
批准号:2206798
-
项目类别:
-
资助金额:$15.45万
-
财政年份:1996
-
负责人:VADIVEL GANAPATHY
-
依托单位:
CELLULAR TARGETS FOR ABUSABLE DRUGS IN HUMAN PLACENTA
-
批准号:2616075
-
项目类别:
-
资助金额:$4.63万
-
财政年份:1996
-
负责人:VADIVEL GANAPATHY
-
依托单位:
海外基金